Lupeol (Synonyms: Clerodol; Monogynol B; Fagarasterol)

Cat. No.: HY-N0790 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC).

For research use only. We do not sell to patients.

Lupeol Chemical Structure

CAS No. : 545-47-1

Size	Price	Stock	Quantity
Free Sample (0.1 - 0.5 mg)		Apply Now
10 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 84	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 144	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 252	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

2 Publications Citing Use of MCE Lupeol

Featured Recommendations

•Related Screening Libraries:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Androgen receptor^[1]

In Vitro

Lupeol, an effective AR inhibitor, can be developed as a potential agent to treat human prostate cancer (CaP). Lupeol (10–50 μM) treatment for 48 h results in a dose-dependent growth inhibition of androgen-dependent phenotype (ADPC) cells viz., LAPC4 and LNCaP cells with an IC₅₀ of 15.9 and 17.3 μM, respectively. Lupeol also inhibits the growth of 22Rν_1 with an IC₅₀ of 19.1 μM. Further, Lupeol inhibits the growth of C4-2b cells with an IC₅₀ of 25 μM. Lupeol has the potential to inhibit the growth of CaP cells of both ADPC and CRPC phenotype. Androgens by activating AR are known to drive the growth of CaP cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lupeol is an effective agent that has the potential to inhibit the tumorigenicity of CaP cells in vivo. At the conclusion of the study on day 56, the total circulating serum-PSA levels (secreted by the implanted tumor cells) are measured. At 56thday post-implantation, PSA levels are observed between 11.95-12.79 ng/mL in control animals with LNCaP-tumors and C4-2b-tumors, respectively. However, Lupeol-treated counterpart animals exhibits reduced serum-PSA levels in a range of 4.25-7.09 ng/mL. Tumor tissues of animals receiving Lupeol treatment exhibits reduced serum-PSA levels as compared to control^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

426.72

Appearance

Solid

Formula

C₃₀H₅₀O

CAS No.

545-47-1

SMILES

C[[email protected]]1([[email protected]@]2(CC[[email protected]@]3([H])C4(C)C)C)[[email protected]@](CC[[email protected]]2([H])[[email protected]]3(CC[[email protected]@H]4O)C)([H])[[email protected]]([[email protected]@H]5C(C)=C)([H])[[email protected]](C)(CC5)CC1

Structure Classification

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

Ethanol : 14.29 mg/mL (33.49 mM; ultrasonic and warming and heat to 60°C)

DMSO : 2 mg/mL (4.69 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3435 mL	11.7173 mL	23.4346 mL
5 mM	0.4687 mL	2.3435 mL	4.6869 mL
10 mM	0.2343 mL	1.1717 mL	2.3435 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: corn oil
Solubility: 20 mg/mL (46.87 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% EtOH 90% corn oil
Solubility: ≥ 1.43 mg/mL (3.35 mM); Clear solution

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (282 KB) SDS (392 KB)

COA (253 KB) HNMR (119 KB)

Handling Instructions (2659 KB)

References

[1]. Siddique HR, et al. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15;17(16):5379-91. [Content Brief]

Cell Assay ^[1]	LAPC4 (wild-functional AR/ADPC); LNCaP (mutant-functional AR/ADPC); 22Rν1 (mutant-functional AR/androgen-independent but responsive); C4-2b cells (mutant-functional AR/CRPC) and PC-3 and DU-145 (lack of endogenous AR) are grown under standard cell culture conditions at 37°C and 5% CO₂ environment. The cells (60-70% confluent) are treated with Lupeol (10-50 μM) for 48 h in complete growth medium. For combination set of experiments, cells are treated with either agonistic androgen-analogue R1881 (1 nM), or antagonist Bicalutamide (10 μM), and/or combination (R1881+Lupeol) for 48 h. After incubation for specified times at 37°C, MTT assay is performed. For sensitization studies, hormone refractory C4-2b cells are treated with Lupeol for 24 h. After 24 h, cells are incubated with Bicalutamide (10 μM) for further 24 h. Cells are assessed for viability^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] Tumor studies are conducted in athymic nude mice and two cohorts of animals are created. 3×10⁶ of cells are injected subcutaneously in the right flanks of each mouse. Each cohort receive a specific cell type either LNCaP or C4-2b. One week post-implantation, twenty mice (with visible tumors) in each cohort are randomly divided into two groups, with 10 animals in each group. The first group of animals receive intraperitoneal (i.p.) administration of corn oil (100 μL) and served as control. The second group of animals receive i.p. administration of Lupeol (40 mg/kg in 100 μL of corn oil) three times/week. Body weights and tumor volumes are recorded. All animals of group 1 and group 2 are sacrificed when tumors cross a pre-set endpoint volume of 1,000 mm³. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Siddique HR, et al. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15;17(16):5379-91. [Content Brief]

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email address *

Phone number *

Organization name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name			Lot #
Applicant Name *			Email address *
Phone number			Department *
Organization name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Lupeol (Synonyms: Clerodol; Monogynol B; Fagarasterol)

Customer Review

2 Publications Citing Use of MCE Lupeol

Featured Recommendations

•Related Screening Libraries:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

Request for HNMR Report